Dayvigo (Lemborexant): EMA vs FDA Regulatory Approach

FDA Approval: Timeline and Evidence Package

The U.S. Food and Drug Administration approved lemborexant (brand name Dayvigo) on December 20, 2019, for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance in adult patients [1]. Eisai submitted a New Drug Application (NDA 212028) supported by two Phase III trials and multiple Phase I pharmacokinetic studies.

SUNRISE-1 (N=1,006), a randomized, double-blind, placebo- and active-controlled trial published in JAMA Network Open, compared lemborexant 5 mg and 10 mg against placebo and zolpidem extended-release 6.25 mg [2]. Over one month, lemborexant 10 mg reduced latency to persistent sleep (LPS) by 10.5 minutes more than placebo (P<0.001) as measured by polysomnography. Both lemborexant doses also significantly improved wake after sleep onset (WASO) compared with zolpidem ER, a finding the FDA specifically noted in its medical review. SUNRISE-2 (N=949) extended the observation period to 12 months, providing longer-term efficacy and safety data that the agency required for a chronic-use indication [3].

The FDA's Division of Psychiatry Products reviewed next-morning driving simulation data, abuse-liability studies in recreational sedative users, and rebound insomnia assessments. The approved label includes a boxed warning about complex sleep behaviors (sleepwalking, sleep-driving) observed across the DORA class [1]. The agency classified lemborexant as a Schedule IV substance under the Controlled Substances Act, consistent with the scheduling of suvorexant (Belsomra), the first DORA approved in 2014 [4].

EMA Authorization: A Narrower Indication

The European Medicines Agency granted centralized marketing authorization for Dayvigo in 2022, but the Committee for Medicinal Products for Human Use (CHMP) placed a more restrictive therapeutic indication on the product. The EMA label limits use to adult patients "whose insomnia is inadequately managed by cognitive behavioral therapy for insomnia (CBT-I) or other non-pharmacological interventions" [5].

This language reflects the EMA's longstanding preference for positioning pharmacotherapy as second-line treatment for chronic insomnia. The European guideline on insomnia, published by the European Sleep Research Society, recommends CBT-I as first-line management [6]. The FDA label, by contrast, carries no explicit requirement for prior non-pharmacological treatment. A U.S. prescriber can initiate lemborexant in a treatment-naive patient at the first visit.

The CHMP's European Public Assessment Report (EPAR) acknowledged the same SUNRISE-1 and SUNRISE-2 datasets but devoted additional scrutiny to the subgroup of elderly patients (aged 65 and older). The EMA required Eisai to provide data on fall risk and next-day cognitive impairment in this population. SUNRISE-1 reported that lemborexant's effect on LPS in older adults was consistent with the overall population, and the incidence of falls during SUNRISE-2 was low (approximately 2% across groups) [2][3]. The agency accepted these findings but required specific product information language advising caution in patients over 75.

Dosing and Label Differences

Both agencies approved 5 mg and 10 mg oral tablet strengths. The recommended starting dose is 5 mg in both jurisdictions. Differences emerge in the conditions for dose escalation and co-administration warnings.

The FDA label permits escalation to 10 mg if the 5 mg dose is tolerated but insufficiently effective [1]. It includes specific pharmacokinetic interaction guidance: when lemborexant is co-administered with moderate CYP3A inhibitors (such as fluconazole or verapamil), the maximum recommended dose drops to 5 mg. Co-administration with strong CYP3A inhibitors (such as itraconazole or clarithromycin) is contraindicated because the expected increase in lemborexant area under the curve (AUC) exceeds 3-fold based on physiologically based pharmacokinetic modeling [1][7].

The EMA's Summary of Product Characteristics (SmPC) includes a similar CYP3A interaction table but additionally advises against use with strong CYP3A inducers (such as rifampicin or carbamazepine), noting that reduced lemborexant plasma concentrations could diminish efficacy [5]. The FDA label mentions this possibility in the clinical pharmacology section but does not raise it to a formal contraindication. This distinction matters for patients on antiepileptic drugs or tuberculosis regimens who may receive different prescribing advice depending on geography.

Neither label recommends dose adjustment for mild-to-moderate hepatic impairment. Both agencies state that lemborexant has not been studied in severe hepatic impairment and is not recommended in that population.

Scheduling and Abuse Potential

The FDA's scheduling decision rested on an eight-way crossover human abuse-potential study comparing lemborexant 10 mg and 20 mg (supratherapeutic) against suvorexant 40 mg, zolpidem 30 mg, and placebo in non-dependent recreational sedative users (N=42) [8]. Lemborexant 10 mg produced "Drug Liking" visual analog scale scores significantly lower than zolpidem 30 mg. The supratherapeutic 20 mg dose was comparable to suvorexant 40 mg. Based on these results, the Drug Enforcement Administration placed lemborexant in Schedule IV.

Europe does not apply a scheduling system analogous to the DEA's five-schedule framework. Instead, individual EU member states manage controlled-substance classification. The EMA flagged the abuse-potential data in the EPAR but deferred national scheduling decisions to member state authorities [5]. In Germany, for example, lemborexant falls under the Arzneimittelverschreibungsverordnung (prescription-only) category without additional narcotic scheduling. This means a European prescriber in certain member states faces fewer administrative steps to prescribe Dayvigo compared with a U.S. prescriber, who must comply with Schedule IV prescription monitoring program requirements.

Real-world surveillance data from the FDA Sentinel System, which monitors claims data for roughly 100 million U.S. lives, has not signaled a disproportionate abuse pattern for lemborexant in the first five years post-approval [9]. The FDA required Eisai to complete a post-marketing abuse-potential study (PMR 3407-1) within seven years of approval.

Post-Market Safety Surveillance

The two agencies diverge in their post-authorization surveillance structures. The FDA issued three post-marketing requirements (PMRs) alongside Dayvigo's approval: a study of abuse potential in the real-world setting, a pediatric pharmacokinetic and safety study (Pediatric Research Equity Act requirement), and a nonclinical carcinogenicity study in rasH2 transgenic mice [1].

The EMA, through its Pharmacovigilance Risk Assessment Committee (PRAC), mandated periodic safety update reports (PSURs) and placed lemborexant on the additional monitoring list, identified by the black triangle symbol (▼) on the packaging [5]. This designation signals to healthcare professionals that any suspected adverse reaction should be reported. The EMA's risk management plan (RMP) also required Eisai to conduct a post-authorization safety study (PASS) specifically examining somnolence-related traffic accidents in European markets.

Differences in the adverse-event databases (FDA Adverse Event Reporting System [FAERS] vs. EudraVigilance) mean that signal detection may occur at different times in each jurisdiction. The 2020 FAERS data for lemborexant showed the most commonly reported adverse events were somnolence, headache, and abnormal dreams, consistent with the clinical trial safety profile [10]. A 2023 disproportionality analysis of FAERS data for DORAs as a class found no new safety signals beyond those identified during pre-approval review [11].

Dr. Emmanuel Mignot, Professor of Sleep Medicine at Stanford University, noted in a 2021 review: "The dual orexin receptor antagonists represent the first mechanistically novel class of insomnia drugs in decades. Their safety profile appears favorable compared with benzodiazepine receptor agonists, but long-term pharmacovigilance data spanning 10 or more years will be necessary to fully characterize rare risks" [12].

Elderly Patients: A Regulatory Focal Point

Both the FDA and EMA paid close attention to the over-65 subgroup, but their label recommendations differ in emphasis. The FDA label states that no dose adjustment is necessary based on age alone, though it notes that elderly patients showed higher lemborexant plasma concentrations (approximately 15% increase in C-max) [1].

The EMA SmPC advises "particular caution" in patients older than 75, citing the theoretical risk of somnolence contributing to falls and fractures [5]. SUNRISE-2 enrolled 187 patients aged 65 and older across all treatment arms. Falls occurred in 1.8% of the lemborexant 5 mg group, 2.1% of the lemborexant 10 mg group, and 1.4% of the placebo group over 12 months [3]. These rates did not reach statistical significance, but the small sample size limited the power to detect a difference. The American Academy of Sleep Medicine's 2023 practice guideline includes lemborexant among recommended pharmacologic options for sleep maintenance insomnia in older adults, conditional recommendation based on moderate-quality evidence [13].

A pooled safety analysis of elderly patients across the SUNRISE program reported that the most common adverse event was somnolence (7.6% lemborexant 10 mg vs. 2.8% placebo), with no cases of next-morning motor vehicle accidents in the trial population [14]. The EMA nevertheless required the PASS on traffic accidents because post-marketing observational data can detect events that controlled trials, with their exclusion criteria and small sample sizes, may miss.

Comparison With the Other Approved DORA

Understanding lemborexant's regulatory path benefits from comparison with suvorexant, approved by the FDA in 2014. The FDA approved suvorexant at doses of 10 mg and 20 mg after the agency's advisory committee expressed concern about next-day somnolence at the originally proposed 30 mg and 40 mg doses [15]. That contentious review set the stage for lemborexant's smoother path through the FDA.

Lemborexant's pharmacokinetic profile differs from suvorexant in half-life. Lemborexant's terminal half-life is approximately 17 hours at the 10 mg dose, compared with approximately 12 hours for suvorexant 20 mg [1][15]. Despite the longer half-life, the FDA concluded that lemborexant's next-morning residual effects were acceptable based on driving simulation data showing no significant impairment at 9 hours post-dose with the 5 mg tablet.

The EMA had not approved suvorexant at the time of lemborexant's European review. Merck withdrew its suvorexant marketing authorization application from the EMA in 2015 before the CHMP reached a final opinion [16]. This means lemborexant was the first DORA available in the European market, a distinction that may have influenced the CHMP's more cautious label language.

Dr. Andrew Krystal, Professor of Psychiatry at UC San Francisco, observed in a 2022 Lancet Neurology commentary: "Europe's first experience with the DORA mechanism coming through lemborexant rather than suvorexant placed an outsized burden of proof on a single compound to establish class-level safety" [17].

What This Means for Prescribers and Patients

For a U.S. prescriber, Dayvigo is a Schedule IV option that can be initiated as first-line pharmacotherapy for insomnia. The label permits doses of 5 mg and 10 mg, with clear CYP3A interaction guidance. Post-market surveillance through FAERS and Sentinel continues to accrue data.

For a European prescriber, Dayvigo is positioned as second-line after non-pharmacological approaches. The EMA's additional monitoring designation (▼) signals that reporting suspected adverse events is especially encouraged during this early post-authorization phase. The SmPC includes stronger caution regarding patients over 75.

Patients who travel between the U.S. and EU should be aware that their lemborexant prescription may face different regulatory treatment at borders depending on the member state's controlled substance classification. Carrying documentation from the prescribing physician simplifies cross-border medication transport.